Patients were aged 18 years or older, had stage IIIb or stage IV ALK-positive NSCLC that had progressed while they were on crizotinib therapy...Tumours with the secondary resistance mutations F1174L/V (objective response in five [71%] of seven patients with this mutation), G1269A (four [67%] of six), C1156Y (five [71%] of seven), and T1151 (two [67%] of three) were especially sensitive to ensartinib...Furthermore, ensartinib had activity against a broad array of ALK mutations, including G1269A, F1174, C1156Y, and T1151….We showed that ensartinib had activity against an array of secondary point mutations to crizotinib, including C1156Y, F1174, G1269A, I1171, L1152R/V, and T1151...